Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan/HCTZ versus candesartan alone in uncontrolled hypertension
2005-005718-19Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2006
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of candesartan and hydrochlorothiazide in hypertension (HTN) (3 arms), sponsored by AstraZeneca. Primary endpoints: Change in sitting diastolic blood pressure, Comparison of sitting diastolic blood pressure lowering: candesartan/HCTZ 32/25 mg versus candesartan 32 mg and 1 more. Started Jun 2006; status: completed.
02
Drugs
candesartanhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2005-005718-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005718-19.